Compare Cassava Sciences Inc (FLNA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Schwab US Dividend Equity ETF — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Schwab US Dividend Equity ETF trades at $33. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SCHD | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $32.83 |
52-Week Low | $1.09 | $26.38 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SCHD trades at $33.00, up 2.48% today with a bullish technical signal from moving averages. The ETF has shown strong performance year-to-date, outperforming the S&P 500 with nearly 30 holdings delivering returns more than double the index. Recent news highlights SCHD's AI stock exposure and dividend focus, though some articles note underperformance against growth stocks in recent months. The fund maintains a 3.2% yield with sustainable dividend growth potential.
SCHD presents a compelling dividend growth opportunity with quality stock selection, though faces competition from higher-yielding alternatives. Key risks include interest rate sensitivity and AI stock concentration. Analyst sentiment remains positive for long-term income investors seeking stable returns with dividend growth exceeding market averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
